AROA Biosurgery's revenue for FY24 climbed 12% year-over-year to NZ$69.1 million ($63.3 million).

Myriad revenue jumped 73% to NZ$23.3 million ($21.4 million), but OviTex/OviTex PRS revenue dropped 7% to NZ$32.6 million ($29.9 million) due to TELA Bio's inventory management.

Product gross margin rose to 85%, with normalised EBITDA loss at NZ$3.1 million ($2.8 million).

For FY25, AROA Biosurgery expects revenue to reach NZ$80-NZ$87 million ($73.3-$79.7 million), driven by Myriad sales and TELA Bio's sales realignment.